Stocktoria
X4 Pharmaceuticals, Inc XFOR
X4 Pharmaceuticals, Inc financials (annual)
Bars are annual figures from 2017 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $35.1M | $2.6M | $0 | $0 | $0 | $3.0M | $0 | $0 | — |
| R&D expense | $72.7M | $81.6M | $72.0M | $61.1M | $50.6M | $41.9M | $30.2M | $20.3M | $17.1M |
| Operating income | -$86.9M | -$36.4M | -$107.5M | -$87.6M | -$85.1M | -$59.9M | -$51.7M | -$29.1M | -$22.2M |
| Interest expense | — | — | $5.8M | $4.0M | $3.6M | $2.7M | $2.1M | $720,000 | $490,000 |
| Income tax | $41,000 | $310,000 | $78,000 | $28,000 | $17,000 | $148,000 | $0 | $0 | — |
| Net income | -$79.2M | -$37.5M | -$101.2M | -$93.9M | -$88.7M | -$62.1M | -$52.8M | -$33.3M | -$22.0M |
| EPS (diluted) | $-1.87 | $-5.59 | $-17.07 | $-1.52 | $-3.99 | $-3.09 | — | — | — |
| Operating cash flow | -$85.6M | -$130.9M | -$96.5M | -$77.1M | -$70.9M | -$58.8M | -$48.1M | -$25.4M | -$21.3M |
| Free cash flow | — | -$131.2M | -$96.6M | -$77.2M | — | — | — | — | — |
| Cash & equivalents | $217.0M | $55.7M | $99.2M | $121.7M | $81.8M | $78.7M | $126.2M | $8.1M | $26.7M |
| Inventory | — | $2.8M | $0 | — | — | — | — | — | — |
| Total assets | $290.5M | $146.4M | $147.3M | $155.6M | $117.2M | $122.9M | $160.7M | $9.9M | $81.3M |
| Total liabilities | $104.2M | $124.3M | $96.2M | $81.5M | $52.8M | $50.1M | $31.5M | $21.6M | $22.5M |
| Shareholders' equity | $186.3M | $22.1M | $51.1M | $74.1M | $64.4M | $72.8M | $129.2M | -$77.1M | -$44.5M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +1250.5% | — | — | — | -100.0% | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.